>
Switch to:

Allergy Therapeutics EV-to-EBIT

: 44.07 (As of Today)
View and export this data going back to 2004. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Allergy Therapeutics's Enterprise Value is $256.4 Mil. Allergy Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $5.8 Mil. Therefore, Allergy Therapeutics's EV-to-EBIT for today is 44.07.

The historical rank and industry rank for Allergy Therapeutics's EV-to-EBIT or its related term are showing as below:

OTCPK:AGYTF' s EV-to-EBIT Range Over the Past 10 Years
Min: -117.34   Med: 11.68   Max: 167.6
Current: 44.82

-117.34
167.6

During the past 13 years, the highest EV-to-EBIT of Allergy Therapeutics was 167.60. The lowest was -117.34. And the median was 11.68.

OTCPK:AGYTF's EV-to-EBIT is ranked lower than
99.99% of the 59 Companies
in the Drug Manufacturers industry.

( Industry Median: 15.13 vs. OTCPK:AGYTF: 44.82 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Allergy Therapeutics's Enterprise Value for the quarter that ended in Jun. 2021 was $109.1 Mil. Allergy Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $5.8 Mil. Allergy Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was 5.33%.


Allergy Therapeutics EV-to-EBIT Historical Data

The historical data trend for Allergy Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.47 -23.71 14.25 7.51 32.26

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.25 - 7.51 - 32.26

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's EV-to-EBIT falls into.



Allergy Therapeutics EV-to-EBIT Calculation

Allergy Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=256.375/5.8176718092567
=44.07

Allergy Therapeutics's current Enterprise Value is $256.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Allergy Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $5.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Allergy Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2021 ) =EBIT / Enterprise Value (Q: Jun. 2021 )
=5.8176718092567/109.05796323983
=5.33 %

Allergy Therapeutics's Enterprise Value for the quarter that ended in Jun. 2021 was $109.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Allergy Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $5.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)